Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas

Histopathology

Volumn 56, Issue 7, 2010, Pages 876-882

  Bakarakos, Panagiotis ^a   Theohari, Irene ^a   Nomikos, Alexandros ^a   Mylona, Eleni ^a   Papadimitriou, Christos ^a   Dimopoulos, Athanasios Meletios ^a   Nakopoulou, Lydia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; Familial; MTOR; PTEN; Sporadic

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; WNT1 PROTEIN; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; AGED; BREAST TUMOR; CARCINOMA; CELL NUCLEUS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; PHOSPHORYLATION; PROPORTIONAL HAZARDS MODELS; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 77953195355     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03570.x     Document Type: Article

References (20)

1. Chow LML, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett. 2006 241 184 196.
2. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol. Med. 2005 11 353 361.
3. Gera JF, Mellinghoff IK, Shi Y et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J. Biol. Chem. 2004 279 2737 2746.
4. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003 361 955 964.
5. Ellenson LH, Wu TC. Focus on endometrial and cervical cancer. Cancer Cell 2004 5 533 538.
6. Marty B, Maire V, Gravier E et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res. 2008 10 R101.
7. Eng G. PTEN: one gene, many syndromes. Hum. Mutat. 2003 22 183 198.
8. Zhou X, Tan M, Stone Hawthorne V et al. Activation of the Aktmammalian target of rapamycin4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin. Cancer Res. 2004 10 6779 6788.
9. Janssen EA, Soiland H, Skaland I et al. Comparing the prognostic value of PTEN and Akt expression with the mitotic activity index in adjuvant chemotherapy-treated node-negative breast cancer patients aged <55 years. Cell Oncol. 2007 29 25 35.
10. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 2003 3 371 377. (Pubitemid 36908940)
11. Nakopoulou L, Lazaris AC, Panayotopoulou EG et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J. Clin. Pathol. 2004 57 523 528.
12. Nakopoulou LL, Tsitsimelis D, Lazaris AC et al. Nm-23, c-erbB-2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters. Cancer Detect. Prev. 1999 23 297 308.
13. Hynes NE, Boulay A. The mTOR pathway in breast cancer. J. Mammary Gland Biol. Neoplasia 2006 11 53 61.
14. Yang Q, Guan K-L. Expanding mTOR signaling. Cell Res. 2007 17 666 681.
15. Zhao H, Cui Y, Dupont J, Sun H, Hennighausen L, Yakar S. Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits Wnt-1-induced mammary tumorigenesis. Cancer Res. 2005 65 6864 6873.
16. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO. The role of PTEN and its signaling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J. Pathol. 2004 204 93 100.
17. Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod. Pathol. 2006 19 238 245.
18. Perez-Tenorio G, Alkhori L, Olsson B et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 2007 13 3577 3584.
19. Lee JS, Kim HS, Kim YB, Lee MC, Park CS, Min KW. Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast. Appl. Immunohistochem. Mol. Morphol. 2004 12 205 210.
20. Haiman CA, Stram DO, Cheng I et al. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2006 15 1021 1025. (Pubitemid 43823533)